Want to see AVR full AI Analyst Report?
Top Page
Anteris Technologies Global Corp.
(NASDAQ:AVR)
Select Model
Select Model
Rating:46Neutral
Price Target:
$8.00
▼(-10.61% Downside)
Action:Reiterated
Date:09/23/26
The score is primarily held down by weak financial performance driven by large operating losses and substantial negative free cash flow, despite a low-debt balance sheet. Technical indicators also lean bearish in the near term (below key moving averages, negative MACD), with only an oversold signal offering some counterbalance. Valuation lacks support due to negative earnings and no dividend, while corporate events are mildly positive but not enough to offset the core profitability and cash-burn risks.
Positive Factors
Low financial leverage
Very low leverage gives Anteris greater financial flexibility while it develops and commercializes its cardiovascular devices. A sizeable equity base can provide more capacity to fund clinical, regulatory, and operating needs without the added pressure of substantial interest obligations.
Negative Factors
Persistent cash burn
Deeply negative operating and free cash flow indicate that Anteris is not yet self-funding its operations. Continued cash burn can require additional financing and may constrain investment in clinical development, regulatory work, and commercialization over the coming quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low leverage gives Anteris greater financial flexibility while it develops and commercializes its cardiovascular devices. A sizeable equity base can provide more capacity to fund clinical, regulatory, and operating needs without the added pressure of substantial interest obligations.
Read all positive factors
Anteris Technologies Global Corp. (AVR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$745.56M
Dividend YieldN/A
Average Volume (3M)679.27K
Price to Earnings (P/E)―
Beta (1Y)1.90
Revenue Growth-9.56%
EPS Growth16.73%
CountryUS
Employees174
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-2.76
Shares Outstanding97,458,470
10 Day Avg. Volume829,638
30 Day Avg. Volume679,268
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-1.98K
Price to Sales (P/S)96.28
P/FCF Ratio-2.31
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.33Price Target Upside71.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.23
Revenue Forecast (FY)$7.16M
Anteris Technologies Global Corp. Business Overview & Revenue Model
Company Description
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering i...
How the Company Makes Money
Anteris primarily seeks to generate revenue through (1) commercialization of its heart valve products and associated proprietary technologies, and (2) partnering and licensing arrangements that allow third parties to use its technology in exchange...
Anteris Technologies Global Corp. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.24M | 1.91M | 2.70M | 2.73M | 3.20M | 5.83M |
| Gross Profit | 829.00K | -317.00K | 1.27M | 876.80K | 298.38K | 1.91M |
| EBITDA | -100.63M | -92.49M | -74.38M | -45.54M | -29.14M | -15.50M |
| Net Income | -103.57M | -94.14M | -76.29M | -46.02M | -30.56M | -17.17M |
Balance Sheet | ||||||
| Total Assets | 272.51M | 23.00M | 80.70M | 30.53M | 15.99M | 21.43M |
| Cash, Cash Equivalents and Short-Term Investments | 257.38M | 12.58M | 70.46M | 21.09M | 9.35M | 15.46M |
| Total Debt | 3.32M | 2.28M | 1.40M | 1.69M | 952.79K | 4.14M |
| Total Liabilities | 20.84M | 23.25M | 18.02M | 11.63M | 6.95M | 10.91M |
| Stockholders Equity | 251.39M | -93.00K | 62.76M | 19.30M | 9.03M | 10.52M |
Cash Flow | ||||||
| Free Cash Flow | -88.06M | -79.76M | -63.51M | -37.03M | -31.08M | -15.02M |
| Operating Cash Flow | -86.26M | -77.80M | -61.24M | -34.63M | -29.42M | -14.44M |
| Investing Cash Flow | -2.00M | -596.00K | -2.28M | -2.58M | -992.57K | -886.07K |
| Financing Cash Flow | 320.72M | 20.55M | 112.83M | 49.34M | 23.27M | 27.42M |
Anteris Technologies Global Corp. Technical Analysis
Negative
8.95
Price Trends
8.56
Negative
8.69
Negative
7.17
Positive
Market Momentum
-0.25
Positive
33.93
Neutral
12.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVR, the sentiment is Negative. The current price of 8.95 is above the 20-day moving average (MA) of 8.42, above the 50-day MA of 8.56, and above the 200-day MA of 7.17, indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 33.93 is Neutral, neither overbought nor oversold. The STOCH value of 12.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVR.
Anteris Technologies Global Corp. Risk Analysis
Anteris Technologies Global Corp. disclosed 66 risk factors in its most recent earnings report. Anteris Technologies Global Corp. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Anteris Technologies Global Corp. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $270.74M | -75.58 | -2.70% | ― | -2.50% | 93.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | $138.80M | -5.96 | -13.17% | ― | 3.15% | 14.61% | |
52 Neutral | $295.26M | -4.84 | -74.06% | ― | -3.95% | -17.90% | |
48 Neutral | $119.21M | -14.32 | -78.70% | ― | 25.59% | 55.35% | |
46 Neutral | $745.56M | -2.79 | -77.66% | ― | -9.56% | 16.73% | |
45 Neutral | $55.68M | -1.00 | -177.04% | ― | 16.13% | -11.56% |
* General Sector Average
AVR
Anteris Technologies Global Corp.
7.69
3.40
79.25%
ANIK
Anika Therapeutics
20.37
11.35
125.83%
APYX
Apyx Medical
2.96
0.94
46.53%
INGN
Inogen
5.36
-2.86
-34.79%
TMCI
Treace Medical Concepts
4.50
-2.16
-32.43%
RPID
Rapid Micro Biosystems
1.11
-2.16
-66.06%
Anteris Technologies Global Corp. Corporate Events
Business Operations and Strategy
Anteris Extends Key Supply and Quality Agreement Term
Positive
Sep 23, 2026
On September 22, 2026, Anteris Aus Operations Pty Ltd and Harvey Industries Group Pty Ltd amended their existing Supply Quality Agreement, originally executed on May 24, 2024, to extend its term. The agreement will now remain in effect until the ...
Business Operations and StrategyExecutive/Board Changes
Anteris Technologies Enhances Executive Equity-Based Compensation Plans
Positive
Sep 17, 2026
On September 12, 2026, Anteris Technologies Global Corp. approved contingent grants of nonqualified stock options and performance-based restricted stock units for Chief Executive Officer Wayne Paterson and senior executive David St Denis, effectiv...
Business Operations and StrategyExecutive/Board Changes
Anteris Technologies Global Appoints New Chief Financial Officer
Positive
Sep 8, 2026
On September 4, 2026, Anteris Technologies Global Corp. appointed veteran finance executive Brent Moen, 59, as Chief Financial Officer, effective September 11, 2026, bringing more than 25 years of experience in capital markets, investor relations,...
Delistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
Court Orders Enable Anteris Trading Halt to Lift
Positive
Aug 3, 2026
On August 3, 2026, Anteris Technologies Global Corp. obtained orders from the Federal Court of Australia rectifying an inadvertent administrative oversight involving the late lodgement of a cleansing notice for 44,068 CHESS Depositary Interests is...
Delistings and Listing ChangesLegal ProceedingsRegulatory Filings and Compliance
Anteris Technologies Requests ASX Trading Halt for Relief
Negative
Jul 31, 2026
On July 31, 2026, Anteris Technologies Global Corp. requested a trading halt in its securities on the Australian Securities Exchange under ASX Listing Rule 17.1, while confirming that trading on the Nasdaq Global Market would remain unaffected. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.